Table 1.
Demographic characteristics and medical history of the patients.
| Baseline characteristics | Mean | SD |
|---|---|---|
| Age | 48.2 | 10.1 |
| Count | Percent | |
| Gender | ||
| Male | 16 | 42.1 |
| Female | 22 | 57.9 |
| Medical history | ||
| Any medical history other than diabetes | 38 | 100 |
| Vitamin D deficiency | 36 | 94.7 |
| Dyslipidemia | 34 | 89.5 |
| Obesity | 27 | 71.1 |
| Hypertension | 23 | 60.5 |
| CKD | 14 | 36.8 |
| Microalbumin | 9 | 64.3∗ |
| Proteinuria | 5 | 35.7∗ |
| Hypothyroidism | 8 | 21.1 |
| Coronary artery disease | 5 | 13.2 |
| Neuropathy | 4 | 10.5 |
| Prior T2DM medications | Median | IQR |
| Number of medications | 2.0 | 3.00 |
| Class of medications | Count | Percent |
| Biguanides | 23 | 60.5 |
| DDP4 inhibitors | 21 | 55.3 |
| Insulin secretagogue | 15 | 39.5 |
| SGLT2 inhibitors | 11 | 28.9 |
| Insulin | 3 | 7.9 |
| GLP1 | 2 | 5.3 |
| Thiazolidinediones | 2 | 5.3 |
| Current T2DM medications | Median | IQR |
| Number of medications | 4.0 | 1.0 |
| Class of medications | Count | Percent |
| Biguanides | 36 | 94.7 |
| SGLT2 inhibitors | 34 | 89.5 |
| DDP4 inhibitors | 21 | 55.3 |
| Insulin secretagogue | 24 | 63.2 |
| Insulin | 22 | 57.9 |
| GLP1 | 18 | 47.4 |
| Thiazolidinediones | 2 | 5.3 |
| Alpha glucosidase inhibitor | 1 | 2.63 |
∗ The percentage was calculated for a total of 14 CKD patients.